Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms – A Focus on Myelofibrosis
Earn up to 1.5 CME/NCPD/CPE Credits/Contact Hours
Date: Wednesday, September 28, 2022
Time: 6:45 PM - 8:15 PM CT
Location: Hilton Americas-Houston – Grand Ballroom ABC, Level 4
Symposium Overview
This satellite symposium will take place in conjunction with the 2022 Society of Hematology Oncology Annual Meeting and will be presented by three renowned experts actively engaged in the care of patients with myelofibrosis.
Target Audience
This activity is intended for community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MF.
Learning Objectives
After participating in the activity, participants should be better able to:
- Develop strategies to personalize care based on risk stratification and symptom burden for patients with myeloproliferative neoplasms
- Review the most recent results from clinical trial investigating emerging treatment options and novel formulations in myelofibrosis
- Identify strategies to monitor and mitigate treatment-related toxicities in patients with myelofibrosis
Accreditation, Support and Credit Statements 
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Bio Ascend. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.5 contact hours (1.5 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-075-L01-P
Type of Activity: Knowledge
Agenda
6:45 PM Welcome, Introductions, and Pre-session Survey
6:50 PM Risk-Stratification and Management Strategies for MPNs
-- Current recommendations in risk-stratification
-- Review the advantage and limitations of MF risk stratification models: IPSS, DIPSS, DIPSS-Plus, GIPSS, MIPSS-70 and
MYSEC-PM
How does risk-stratification inform treatment decisions?
--Recommended treatement options for asymptomatic, low,-intermediate- and high-risk patients with MF
7:05 PM Therapeutic Options for Patients with JAK-Inhibitor-Naive Myelofibrosis
-- Review of the treatment landscape and unmet needs
-- Strategies to mitigate treatment-related toxicities
-- Case Study 1 – JAK-Inhibitor Navie patient with MF
7:25 PM Discussion and Audience Q&A
7:35 PM Treatment Selection and Emerging Therapeutic Options in JAK-Inhibitor Refractory/Intolerant Myelofibrosis
-- Summarize efficacy and safety results from recent clinical trials
-- Selection and sequencing of therapy
-- Strategies to mitigate treatment-related toxicities
-- Case Study 2 – JAK-inhibitor refractory MF
8:05 PM Summary and Post-Session Survey
8:15 PM Adjourn
Chair
Srdan Verstovsek, MD, PhD
United Energy Resources, Inc.
Professor of Medicine
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Faculty
Elizabeth Hexner, MD
Medical Director, Center for Cellular Immunotherapies
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Naveen Pemmaraju, MD
Associate Professor
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Support Statement
This CE activity is supported through educational grants from CTI Biopharma Corp.and Sierra Oncology, a GSK company.
You must be registered for SOHO Annual Meeting to register for this symposium. Please visit: www.soho.click/2022 to register for the SOHO 2022 Annual Meeting.
This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.